PFS and OS from the times of randomization and crossover with attention to the effects of cytogenetic abnormalities. (A) PFS: Estimated 1-year PFS rate was 78% with LEN + DEX and 52% with DEX (P = .0003). (B) OS: No difference is apparent between arms. (C) OS according to the presence or absence of CAs: patients without CAs had superior OS, regardless of treatment arm. No statistically significant OS differences between LEN-DEX and DEX could be demonstrated within the CA and no CA groups. Testing CA versus No CA within treatment groups: LEN-DEX, P = .09; DEX, P = .03. Testing LEN-DEX versus DEX within CA groups: CA, P = .42; No CA, P = .7. (D) PFS and OS after crossover from DEX to LEN-DEX.